Matsumoto
Matsumoto
Matsumoto, Japan16 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting | Nutritional and Metabolic Diseases, amyloidosis, cardiomyopathy, cardiovascular disorder, heart disorder, metabolic disease, proteostasis deficiencies | Recruiting | Not stated | 2026-10-09 | NCT07358078 | |
| A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) | Arterial Occlusive Diseases, arteriosclerosis disorder, atherosclerosis, cardiovascular disorder, vascular disorder | Active, not recruiting | Phase 3 | 2026-10-08 | NCT06292013 | |
| Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 3 | 2026-10-08 | NCT05899608 | |
| Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension | lung disorder, pulmonary arterial hypertension, pulmonary hypertension, respiratory system disorder | Active, not recruiting | Phase 3 | 2026-10-06 | NCT04273945 | |
| A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis | Digestive System Diseases, colitis, colonic disorder, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, ulcerative colitis | Active, not recruiting | Phase 3 | 2026-09-28 | NCT05528510 | |
| A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis | Digestive System Diseases, colitis, colonic disorder, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, ulcerative colitis | Active, not recruiting | Phase 2 / Phase 3 | 2026-09-28 | NCT04033445 | |
| A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants | Crohn disease, Digestive System Diseases, Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, Spondylarthritis, Spondylarthropathies, arthritic joint disease, arthropathy, autoimmune disease, bone disorder, colitis, colonic disorder, connective tissue disorder, digestive system disorder, gastroenteritis, immune system disorder, inflammatory bowel disease, intestinal disorder, juvenile idiopathic arthritis, musculoskeletal system disorder, psoriasis, psoriatic arthritis, rheumatic disorder, skin disorder, spondylitis, ulcerative colitis, vertebral column disorder | Recruiting | Phase 3 | 2026-09-25 | NCT06663332 | |
| A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis | Digestive System Diseases, colitis, colonic disorder, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, ulcerative colitis | Active, not recruiting | Phase 3 | 2026-09-25 | NCT06260163 | |
| A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 3 | 2026-09-25 | NCT05455320 | |
| A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 3 | 2026-09-25 | NCT05083169 | |
| A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, cardiovascular disorder, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 2 | 2026-09-25 | NCT04634552 | |
| Psoriasis Longitudinal Assessment and Registry | Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, Spondylarthritis, Spondylarthropathies, arthritic joint disease, arthropathy, bone disorder, musculoskeletal system disorder, psoriasis, psoriatic arthritis, skin disorder, spondylitis, vertebral column disorder | Active, not recruiting | Not stated | 2026-09-25 | NCT00508547 | |
| A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies | muscle tissue disorder, musculoskeletal system disorder, myositis disease, nervous system disorder, neuromuscular disease | Active, not recruiting | Phase 2 | 2026-09-21 | NCT05379634 | |
| Selatogrel Outcome Study in Suspected Acute Myocardial Infarction | acute myocardial infarction | Enrolling by invitation | Phase 3 | 2026-07-23 | NCT04957719 | |
| An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) | Nutritional and Metabolic Diseases, amyloidosis, metabolic disease, proteostasis deficiencies | Enrolling by invitation | Phase 3 | 2026-04-17 | NCT05667493 | |
| A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-04-02 | NCT05514054 |